Half-Year 2022 Financial and Clinical Trials Update

Roche Enspryng (satralizumab, RG6168, SA237) Anti-IL-6 receptor humanized monoclonal antibody Indication Generalised myasthenia gravis (MG) Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) Phase/study # of patients Phase III Luminesce N=240 • ARM A: Enspryng plus standard of care Design Primary endpoint Status CT Identifier • ARM B: Placebo plus standard of care ■ Mean change from baseline in total MG-ADL score at week 24 in AChR+ population Orphan Drug Designation granted in US Q1 2021 FPI Q4 2021 NCT04963270 Phase III METEOROID N=152 ⚫ARM A: Enspryng at weeks 0, 2, 4 (loading doses) and maintenance doses q4w ⚫ARM B: Placebo ■ Time from randomization to the first occurrence of a MOGAD relapse ■ FPI expected Q3 2022 Orphan Drug Designation granted by FDA in Q4 2021 In collaboration with Chugai MG-ADL= Myasthenia Gravis Activities of Daily Living; AChR-Acetylcholine receptor; MOGAD-Myelin Oligodendrocyte Glycoprotein Antibody Disease NCT05271409 112 Neuroscience

View entire presentation